ResMed has demonstrated a strong financial performance with an 11% revenue growth in the second quarter of fiscal 2026, reporting an EPS of $2.81 that exceeded expectations by 46%. Analysts have responded positively, raising price targets for the company, which is viewed as undervalued despite solid cash flow and future projections. The FDA's recent clearance of its innovative AI-enabled device, Smart Comfort, further enhances its competitive positioning in the medical technology sector.
Loading timeline…
